At the news
? NEUTRALIMPACT 5/10 PRESS-RELEASE filed Aug 12, 2026 at 06:50 ET
Pharvaris reported Q2 2026 results with a loss per share of €0.70, slightly above the consensus EPS estimate of -$0.65 (per ADS) but the comparison is not directly comparable due to currency and share basis differences. The key event is the expected topline data from the CHAPTER-3 Phase 3 study of deucrictibant XR for HAE prophylaxis in 3Q2026, which is the primary stock-moving catalyst.
- Cash and cash equivalents of €318 million as of June 30, 2026, extending cash runway into 2028
- Loss for Q2 2026 was €47.8 million, or €0.70 per share, vs €45.5 million (€0.83 per share) in Q2 2025
- Topline data from CHAPTER-3 Phase 3 study of deucrictibant XR for HAE prophylaxis expected in 3Q2026
- FDA accepted NDA for deucrictibant IR with PDUFA date of April 23, 2027; EMA validated MAA in July 2026
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access